Neurocrine Biosciences (NBIX) Set to Announce Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) will issue its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $1.48 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The company had revenue of $590.20 million for the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 earnings per share. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Neurocrine Biosciences Stock Up 0.1 %

NBIX stock opened at $116.20 on Tuesday. The company has a market capitalization of $11.73 billion, a price-to-earnings ratio of 35.11 and a beta of 0.36. Neurocrine Biosciences has a 12 month low of $103.63 and a 12 month high of $157.98. The firm has a 50 day moving average of $122.86 and a two-hundred day moving average of $133.98.

Analysts Set New Price Targets

Several analysts have commented on NBIX shares. Oppenheimer boosted their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Morgan Stanley boosted their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. Citigroup boosted their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Insider Activity

In related news, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the completion of the sale, the chief financial officer now owns 31,528 shares in the company, valued at $4,741,180.64. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Neurocrine Biosciences news, CFO Matt Abernethy sold 14,100 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the sale, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at approximately $4,741,180.64. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,968 shares of company stock worth $8,999,632. 4.30% of the stock is currently owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.